USFDA cautions Aurobindo Pharma's oral solids formulation facility of regulatory action

According to USFDA's definitions, OAI means "objectionable conditions
were found and regulatory administrative sanctions by FDA are
indicated" during inspections. The company said that it believes that
this OAI classification will not have any material impact on the
existing revenues or the supplies to its US business at this juncture.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-cautions-aurobindo-pharmas-oral-solids-formulation-facility-of-regulatory-action/articleshow/73761421.cms

Comments

Popular posts from this blog

Lupin, Aurobindo units recall products in US market

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply

Data Analyst Jobs – Life Sciences Apply at Cognizant